Evidence map›Paper›PMID 39426992›Full record

ArticleScientific reports2024

Nationwide study on development and validation of a risk prediction model for CIN3+ and cervical cancer in Estonia.

Anna Tisler, Andres Võrk, Martin Tammemägi, Sven Erik Ojavee, Mait Raag, Aleksandra Šavrova, Mari Nygård, Jan F Nygård, Mindaugas Stankunas, Anda Kivite-Urtane and 1 more

Abstract readValidation Study
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Anna TislerInstitute of Family Medicine and Public Health, University of Tartu, Ravila 19, 50411, Tartu, Estonia. anna.tisler@ut.ee.
Andres VõrkJohan Skytte Institute of Political Studies, University of Tartu, Tartu, Estonia.
Martin TammemägiDepartment of Health Sciences, Brock University, St Catharines, ON, Canada.
Sven Erik OjaveeDepartment of Computational Biology, University of Lausanne, Lausanne, Switzerland.
Mait RaagInstitute of Family Medicine and Public Health, University of Tartu, Ravila 19, 50411, Tartu, Estonia.
Aleksandra ŠavrovaNorth Estonia Medical Centre, Women's Clinic, Tallinn, Estonia.
Mari NygårdCancer Registry of Norway, Norwegian Institute of Public Health, Oslo, Norway.
Jan F NygårdCancer Registry of Norway, Norwegian Institute of Public Health, Oslo, Norway.
Mindaugas StankunasDepartment of Health Management, Lithuanian University of Health Sciences, Kaunas, Lithuania.
Anda Kivite-UrtaneInstitute of Public Health, Riga Stradins University, Riga, Latvia.
Anneli UuskülaInstitute of Family Medicine and Public Health, University of Tartu, Ravila 19, 50411, Tartu, Estonia.

Funding

Eesti Teadusagentuur PRG2218European Economic Area EMP416
6 · The paper itself

Abstract

Transitioning to an individualized risk-based approach can significantly enhance cervical cancer screening programs. We aimed to derive and internally validate a prediction model for assessing the risk of cervical intraepithelial neoplasia grade 3 or higher (CIN3+) and cancer in women eligible for screening. This retrospective study utilized data from the Estonian electronic health records, including 517,884 women from the health insurance database and linked health registries. We employed Cox proportional hazard regression, incorporating reproductive and medical history variables (14 covariates), and utilized the least absolute shrinkage and selection operator (LASSO) for variable selection. A 10-fold cross-validation for internal validation of the model was used. The main outcomes were the performance of discrimination and calibration. Over the 8-year follow-up, we identified 1326 women with cervical cancer and 5929 with CIN3+, with absolute risks of 0.3% and 1.1%, respectively. The prediction model for CIN3 + and cervical cancer had good discriminative power and was well calibrated Harrell's C of 0.74 (0.73-0.74) (calibration slope 1.00 (0.97-1.02) and 0.67 (0.66-0.69) (calibration slope 0.92 (0.84-1.00) respectively. A developed model based on nationwide electronic health data showed potential utility for risk stratification to supplement screening efforts. This work was supported through grants number PRG2218 from the Estonian Research Council, and EMP416 from the EEA (European Economic Area) and Norway Grants.

Indexed as

Uterine Cervical DysplasiaUterine Cervical NeoplasmsAdultAgedEarly Detection of CancerEstoniaFemaleHumansMiddle AgedProportional Hazards ModelsRetrospective StudiesRisk AssessmentCervical cancerHealth dataHigh-grade lesionsModelPredictionScreening

Identifiers

PMID39426992
PMCPMC11490536

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.